Bli medlem
Bli medlem

Du är här


OASMIA PHARMACEUTICAL AB: Clarification of article in BioPharm Insight

Oasmia Pharmaceutical AB
Company Announcement

Clarification of article in BioPharm Insight

Uppsala, Sweden, 2016-05-11 10:20 CEST (GLOBE NEWSWIRE) --

Oasmia Pharmaceutical AB is currently, which previously have been communicated,
in on-going negotiations with different parties regarding out-licensing of the
XR17 platform as well as the company’s product candidates, with focus on
Paclical®/Apealea®. In line with past commercial agreements closed by the
company, we see future agreements containing both large signing payments in
combination with milestone payments when certain events have occurred and an
additional royalty component.

It is hard to predict the timing for finalization of agreements.

The company has not had the opportunity to comment on the article before

About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops, manufactures, markets and sells new
generations of drugs in the field of human and veterinary oncology. The
company’s product development aims to create and manufacture novel nanoparticle
formulations and drug-delivery systems based on well-established cytostatics
which, in comparison with current alternatives, show improved properties,
reduced side-effects, and expanded applications. The company’s product
development is based on its proprietary in-house research and company patents.
Oasmia is listed on NASDAQ Capital Markets (OASM.US), Frankfurt Stock Exchange
(OMAX.GR, ISIN SE0000722365) and NASDAQ Stockholm (OASM.ST).

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.